Drug discovery is changing. Deep generative models, as being pioneered by our guest Dr. Alex Zhavoronkov, founder and CEO of InSilico Medicine, are able to generate entirely new molecules and even, as we’ll hear, can discover new targets altogether. Within days.
This fall, InSilico and collaborators published an application of their generative reinforcement learning (GENTRL) to generate tens of thousands of novel compounds, synthesized only the 6 best, and identified a selective and nanomolar-potent candidate among them. We discuss deep generative drug discovery models, promise and criticism on these new methodologies, and dive into new research from their pending publications on NASH and we hear about a breaking new contribution by the InSilico team regarding a potential treatment for CoronaVirus. This is the TomorrowScale Podcast. I’m Justin Briggs.
“Deep learning enables rapid identification of potent DDR1 kinase inhibitors” (Zhavoronkov 2019)
“Reply to: Assessing the Impact of Generative AI on Medicinal Chemistry” (Zhavoronkov 2020)
InSilico Medicine: https://insilico.com
Listen on Your Favorite Podcast App
The TomorrowScale Podcast was created to showcase scientists and entrepreneurs who are building science-based businesses, and to hear their stories from the benches and in the trenches of research & development. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thanks to our guests for sharing their time and knowledge with us. Thank you for listening. Please science responsibly.